NCCM
ADMS

Nine Chapters Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Nine Chapters Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-23,000
Closed -$385K – 669
2015
Q3 		$385K Buy
+23,000
New +$523K 0.03% 639

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nine Chapters Capital Management's ADMS Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2015, closing a stake of 23,000 shares — an estimated $385K sold.

Nine Chapters Capital Management first reported a position in ADMS in Q3 2015 and held it in 1 quarter. The position peaked at $385K in Q3 2015. 93 funds tracked by Wall St. Rank hold ADMS as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 23,000 Adamas Pharmaceuticals shares in Q4 2015, an estimated $385K.
  • Nine Chapters Capital Management first reported a position in Adamas Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Nine Chapters Capital Management's Adamas Pharmaceuticals position peaked at $385K in Q3 2015.
  • 93 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.